Michael L Cheng1,2, Christie J Lau3, Marina S D Milan1, Julianna G Supplee3, Jonathan W Riess4, Penelope A Bradbury5, Pasi A Jänne1,2,3, Geoffrey R Oxnard1,2, Cloud P Paweletz3. 1. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. 3. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA. 4. University of California Davis Comprehensive Cancer Center, Sacramento, CA. 5. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Abstract
Plasma circulating tumor DNA (ctDNA) analysis is routine for genotyping of advanced non-small-cell lung cancer (NSCLC); however, early response assessment using plasma ctDNA has yet to be well characterized. MATERIALS AND METHODS: Patients with advanced EGFR-mutant NSCLC across three phase I NCI osimertinib combination trials were analyzed in this study, and an institutional cohort of patients with KRAS-, EGFR-, and BRAF-mutant advanced NSCLC receiving systemic treatment was used for validation. Plasma was collected before treatment initiation and serially before each cycle of therapy, and key driver mutations in ctDNA were characterized by droplet digital polymerase chain reaction. Timing of plasma versus imaging response was compared in a separate cohort of patients with EGFR-mutant NSCLC treated with osimertinib. Across cohorts, we also studied ctDNA variability before treatment start. RESULTS: In the NCI cohort, 14/16 (87.5%) patients exhibited ≥ 90% decrease in mutation abundance by the first on-treatment timepoint (20-28 days from treatment start) with minimal subsequent change. Similarly, 47/56 (83.9%) patients with any decrease in the institutional cohort demonstrated ≥ 90% decrease in mutation abundance by the first follow-up draw (7-30 days from treatment start). All 16 patients in the imaging cohort with radiographic partial response showed best plasma response within one cycle, preceding best radiographic response by a median of 24 weeks (range: 3-147 weeks). Variability in ctDNA levels before treatment start was observed. CONCLUSION: Plasma ctDNA response is an early phenomenon, with the majority of change detectable within the first cycle of therapy. These kinetics may offer an opportunity for early insight into treatment effect before standard imaging timepoints.
Plasma circulating tumor DNA (ctDNA) analysis is routine for genotyping of advanced non-small-cell lung cancer (NSCLC); however, early response assessment using plasma ctDNA has yet to be well characterized. MATERIALS AND METHODS: Patients with advanced EGFR-mutant NSCLC across three phase I NCI osimertinib combination trials were analyzed in this study, and an institutional cohort of patients with KRAS-, EGFR-, and BRAF-mutant advanced NSCLC receiving systemic treatment was used for validation. Plasma was collected before treatment initiation and serially before each cycle of therapy, and key driver mutations in ctDNA were characterized by droplet digital polymerase chain reaction. Timing of plasma versus imaging response was compared in a separate cohort of patients with EGFR-mutant NSCLC treated with osimertinib. Across cohorts, we also studied ctDNA variability before treatment start. RESULTS: In the NCI cohort, 14/16 (87.5%) patients exhibited ≥ 90% decrease in mutation abundance by the first on-treatment timepoint (20-28 days from treatment start) with minimal subsequent change. Similarly, 47/56 (83.9%) patients with any decrease in the institutional cohort demonstrated ≥ 90% decrease in mutation abundance by the first follow-up draw (7-30 days from treatment start). All 16 patients in the imaging cohort with radiographic partial response showed best plasma response within one cycle, preceding best radiographic response by a median of 24 weeks (range: 3-147 weeks). Variability in ctDNA levels before treatment start was observed. CONCLUSION: Plasma ctDNA response is an early phenomenon, with the majority of change detectable within the first cycle of therapy. These kinetics may offer an opportunity for early insight into treatment effect before standard imaging timepoints.
Authors: Adrian G Sacher; Cloud Paweletz; Suzanne E Dahlberg; Ryan S Alden; Allison O'Connell; Nora Feeney; Stacy L Mach; Pasi A Jänne; Geoffrey R Oxnard Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777
Authors: Rajiv Raja; Michael Kuziora; Philip Z Brohawn; Brandon W Higgs; Ashok Gupta; Phillip A Dennis; Koustubh Ranade Journal: Clin Cancer Res Date: 2018-08-09 Impact factor: 12.531
Authors: Anne Marie Lennon; Adam H Buchanan; Isaac Kinde; Andrew Warren; Ashley Honushefsky; Ariella T Cohain; David H Ledbetter; Fred Sanfilippo; Kathleen Sheridan; Dillenia Rosica; Christian S Adonizio; Hee Jung Hwang; Kamel Lahouel; Joshua D Cohen; Christopher Douville; Aalpen A Patel; Leonardo N Hagmann; David D Rolston; Nirav Malani; Shibin Zhou; Chetan Bettegowda; David L Diehl; Bobbi Urban; Christopher D Still; Lisa Kann; Julie I Woods; Zachary M Salvati; Joseph Vadakara; Rosemary Leeming; Prianka Bhattacharya; Carroll Walter; Alex Parker; Christoph Lengauer; Alison Klein; Cristian Tomasetti; Elliot K Fishman; Ralph H Hruban; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos Journal: Science Date: 2020-04-28 Impact factor: 47.728
Authors: Natasha B Leighl; Ray D Page; Victoria M Raymond; Davey B Daniel; Stephen G Divers; Karen L Reckamp; Miguel A Villalona-Calero; Daniel Dix; Justin I Odegaard; Richard B Lanman; Vassiliki A Papadimitrakopoulou Journal: Clin Cancer Res Date: 2019-04-15 Impact factor: 12.531
Authors: Aadel A Chaudhuri; Jacob J Chabon; Alexander F Lovejoy; Aaron M Newman; Henning Stehr; Tej D Azad; Michael S Khodadoust; Mohammad Shahrokh Esfahani; Chih Long Liu; Li Zhou; Florian Scherer; David M Kurtz; Carmen Say; Justin N Carter; David J Merriott; Jonathan C Dudley; Michael S Binkley; Leslie Modlin; Sukhmani K Padda; Michael F Gensheimer; Robert B West; Joseph B Shrager; Joel W Neal; Heather A Wakelee; Billy W Loo; Ash A Alizadeh; Maximilian Diehn Journal: Cancer Discov Date: 2017-09-24 Impact factor: 39.397
Authors: Qu Zhang; Jia Luo; Han Si; Shaad E Abdullah; Brandon W Higgs; Todd Hembrough; Song Wu; Chen Gao; Wenjing Xu; Phillip A Dennis; Michiel S van der Heijden; Neil H Segal; Jamie E Chaft; J Carl Barrett; Matthew D Hellmann Journal: Cancer Discov Date: 2020-08-14 Impact factor: 39.397
Authors: Geoffrey R Oxnard; Yuebi Hu; Kathryn F Mileham; Hatim Husain; Daniel B Costa; Philip Tracy; Nora Feeney; Lynette M Sholl; Suzanne E Dahlberg; Amanda J Redig; David J Kwiatkowski; Michael S Rabin; Cloud P Paweletz; Kenneth S Thress; Pasi A Jänne Journal: JAMA Oncol Date: 2018-11-01 Impact factor: 31.777
Authors: Stephanie J Yaung; Corinna Woestmann; Christine Ju; Xiaoju Max Ma; Sandeep Gattam; Yiyong Zhou; Liu Xi; Subrata Pal; Aarthi Balasubramanyam; Nalin Tikoo; Claus Peter Heussel; Michael Thomas; Mark Kriegsmann; Michael Meister; Marc A Schneider; Felix J Herth; Birgit Wehnl; Maximilian Diehn; Ash A Alizadeh; John F Palma; Thomas Muley Journal: Cancers (Basel) Date: 2022-05-18 Impact factor: 6.575